Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study.

< BACK TO ARCHIVE


2022 Feb


Ann Transl Med


http://www.ncbi.nlm.nih.gov/pubmed/35280395?dopt=Abstract


10


4

Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study.

Authors

Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study.
Zheng X, Tao G, Sun S, Jin X, Chen Y, Zhang Y, Sun J, Huang P
Ann Transl Med. 2022 Feb; 10(4):183.
PMID: 35280395.

Abstract

Programmed death-1 (PD-1) inhibitors have been approved and are currently widely used to treat lung cancer patients. However, comparative data on the adverse events (AEs) associated with different PD-1 inhibitors are very limited.
Read This Paper